Grand Pharmaceutical (China) Co., Ltd.

Grand Pharmaceutical (China) Co., Ltd. (referred to as Wuyao) was founded in 1939 in the Taihang Mountain Revolutionary Base. Blockade is one of the conditions for defeating the enemy." After more than 60 years of development, Wuyao has become a modern Sino-foreign joint venture pharmaceutical company with a registered capital of 85 million yuan, an area of 280 mu, and a construction area of 93,000 square meters. The company's main products are pharmaceutical preparations, pharmaceutical raw materials and intermediates, with an annual sales income of 400 million yuan and annual foreign exchange earnings of 15 million US dollars. It has an annual production of 200 million liquid preparations, more than 4 billion solid preparations, and more than 4,000 tons of raw materials. It is a designated enterprise for emergency medicine and narcotics in the national combat readiness reserve.

Visit Website

Tan Shize(CEO)

medicine and narcotics

Above 10M USD

11

Nestled in the historic Taihang Mountain Revolutionary Base, Grand Pharmaceutical (China) Co., Ltd., affectionately known as Wuyao, embodies a legacy of resilience and innovation in the realm of pharmaceutical excellence. Founded in 1939 with a steadfast commitment to service under challenging conditions, Wuyao has evolved over more than six decades into a prominent Sino-foreign joint venture pharmaceutical powerhouse. Our journey began with a vision to serve the community through pharmaceutical preparations, raw materials, and intermediates of the highest quality. Spanning 280 mu of land with a sprawling construction area of 93,000 square meters, our facilities in Wuhan stand as a testament to our dedication to advancing healthcare solutions. With a registered capital of 85 million yuan, we have established ourselves as a cornerstone of the pharmaceutical industry, achieving an annual sales income of 400 million yuan and foreign exchange earnings totaling 15 million US dollars. At the heart of our operations lie our state-of-the-art production capabilities: producing 200 million liquid preparations annually, over 4 billion solid preparations, and more than 4,000 tons of raw materials. This extensive production capacity positions us as a designated enterprise for emergency medicines and narcotics in the national combat readiness reserve, underscoring our commitment to national health security. Led by visionary Tan Shize, our dedicated team in Wuhan exemplifies our core values of integrity, innovation, and excellence in every aspect of our operations. From research and development to manufacturing and distribution, every step of our process adheres to stringent quality standards to ensure the safety and efficacy of our products. As we continue to expand our global footprint, our website [www.wuhan-pharm.com](http://www.wuhan-pharm.com) serves as a gateway to explore our comprehensive portfolio of pharmaceutical innovations. Join us on our journey as we redefine the boundaries of healthcare, striving to improve the lives of millions worldwide through pioneering medical solutions. Discover Grand Pharmaceutical (China) Co., Ltd., where tradition meets cutting-edge technology to shape the future of healthcare with compassion and commitment.